Colitis / Crohn’s
Peptides researched for ulcerative colitis and Crohn’s disease — mucosal healing, intestinal anti-inflammatory activity, fistula repair, and immune normalization. Each compound below links to its full dosing protocol.
Research Use Only. All dosing information is for educational purposes. Consult a licensed healthcare provider before making health decisions.
KPV
A tripeptide (Lys-Pro-Val) derived from α-MSH with strong anti-inflammatory activity targeted at the intestinal epithelium. KPV is taken up by the PepT1 transporter expressed on gut epithelial cells — the same transporter upregulated during IBD flares — making it one of the most directly colitis-relevant peptides in the research literature.
Route: Subcutaneous injection or Oral
Reconstitution: 3.0 mL bacteriostatic water → 3.33 mg/mL
Dose Range: 200–500 mcg once daily (titrate up)
Cycle: 8–12 weeks (up to 16 weeks)
Schedule: Week 1: 200 mcg → Week 2: 300 mcg → Week 3: 400 mcg → Weeks 4–8: 500 mcg
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — Gastroenterology, 2008
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD — Inflamm Bowel Dis, 2008
- Orally Targeted Delivery of Tripeptide KPV Efficiently Alleviates Ulcerative Colitis — Mol Ther, 2017
BPC-157
Body Protection Compound-157, a stable gastric pentadecapeptide originally studied as an anti-ulcer agent. In colitis and Crohn’s models it is researched for healing intestinal mucosa and anastomoses, repairing fistulas, counteracting ulcer formation, and reducing bowel-wall inflammation while supporting the gut-brain axis.
Route: Subcutaneous injection
Reconstitution: 3.0 mL bacteriostatic water → 1.67 mg/mL
Dose Range: 200–600 mcg once daily (titrate up)
Cycle: 8–12 weeks (up to 16 weeks)
Schedule: Weeks 1–2: 200 mcg → Weeks 3–4: 400 mcg → Weeks 5–8+: 600 mcg
- New studies with stable gastric pentadecapeptide protecting gastrointestinal tract — Inflammopharmacology, 2024
- Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy — Curr Pharm Des, 2020
- BPC 157 and Standard Angiogenic Growth Factors: GI Tract Healing — Curr Pharm Des, 2018
TB-500
A synthetic fragment of thymosin beta-4 (Tβ4), the actin-regulating repair peptide. In experimental colitis, recombinant Tβ4 is researched for reducing intestinal inflammation and fibrosis — a key concern in stricturing Crohn’s disease — and for promoting mucosal repair. Often stacked with BPC-157 (the “Wolverine” blend) for synergistic tissue healing.
Route: Subcutaneous injection
Reconstitution: 3.0 mL bacteriostatic water → 1.67 mg/mL
Dose Range: 500–1000 mcg once daily (gradual titration)
Cycle: 8–12 weeks (up to 16 weeks)
Schedule: Weeks 1–2: 500 mcg → Weeks 3–4: 600 mcg → Weeks 5–8: 750 mcg → Weeks 9–12: 1000 mcg
- Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis — Mol Biomed, 2026
- Recombinant adeno-associated virus carrying thymosin β4 suppresses experimental colitis in mice — World J Gastroenterol, 2017
- Progress on the Function and Application of Thymosin β4 — Front Endocrinol, 2021
Thymosin Alpha-1 (TA1)
An immunomodulatory peptide that normalizes T-cell balance and regulatory immune responses. Colitis and Crohn’s involve systemic immune dysregulation beyond the gut lining; TA1 is researched for restoring Th1/Th17/Treg balance, supporting immune tolerance, and reducing the systemic inflammatory burden that perpetuates intestinal inflammation.
Route: Subcutaneous injection
Reconstitution: 3.0 mL bacteriostatic water → 1.67 mg/mL
Dose Range: 300–500 mcg once daily (gradual titration)
Cycle: 8–12 weeks (up to 16 weeks)
Schedule: Week 1: 300 mcg → Weeks 2–8: 500 mcg (≈3.5 mg/week)
- Design and Development of a Novel Peptide for Treating Intestinal Inflammation — Front Immunol, 2019
- Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials — Altern Ther Health Med, 2024
- Thymosin α1 and Its Role in Viral Infectious Diseases: Mechanism and Clinical Application — Molecules, 2023
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).